FNY Investment Advisers, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 44 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
FNY Investment Advisers, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2020$18,000
+28.6%
56,500
+175.6%
0.01%
+250.0%
Q4 2019$14,000
+16.7%
20,500
+10.8%
0.00%0.0%
Q3 2019$12,000
+500.0%
18,500
+1056.2%
0.00%
+300.0%
Q2 2019$2,000
-99.5%
1,600
-98.0%
0.00%
-98.9%
Q3 2018$402,00079,7790.09%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2019
NameSharesValueWeighting ↓
PERKINS CAPITAL MANAGEMENT INC 2,426,300$802,0000.74%
Cowen Prime Services LLC 1,411,500$466,0000.23%
GSA CAPITAL PARTNERS LLP 1,205,873$398,0000.07%
Nantahala Capital Management 5,113,958$1,690,0000.05%
HighMark Wealth Management LLC 80,000$26,0000.02%
Kalos Management, Inc. 72,858$24,0000.01%
Qube Research & Technologies Ltd 585,187$193,0000.00%
WINTON GROUP Ltd 190,146$63,0000.00%
Ironwood Financial, llc 1,571$1,0000.00%
Virtu Financial LLC 12,049$4,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders